NCT05056974View on ClinicalTrials.gov

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

PHASE2CompletedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

December 2, 2021

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions

HIV-1 Infection

Interventions

BIOLOGICAL

UB-421

10 mg/kg, weekly UB-421 during the 8-week

DRUG

chidamide

10 mg/dose, twice a week for 8 weeks

Trial Locations (1)

Unknown

Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan

Sponsors

Lead Sponsor

United BioPharma

All Listed Sponsors

lead

United BioPharma

INDUSTRY

NCT05056974 - A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs | Biotech Hunter | Biotech Hunter